Welcome to our dedicated page for Seer news (Ticker: SEER), a resource for investors and traders seeking the latest updates and insights on Seer stock.
Seer, Inc. (SEER) is a pioneering life sciences company advancing proteomic research through its innovative Proteograph Product Suite. This page aggregates official news and developments related to the company's transformative nanoparticle technology, strategic partnerships, and research breakthroughs.
Investors and researchers will find timely updates including earnings reports, product innovations, and scientific collaborations. Our curated collection features press releases on financial results, technology validations, and operational milestones that demonstrate SEER's leadership in unbiased proteomic analysis.
The news hub covers essential developments across three key areas: financial performance updates, advancements in multi-omics research capabilities, and strategic alliances with biopharma partners. Users can track how SEER's automated workflows and engineered nanoparticles continue to redefine large-scale protein studies.
Bookmark this page for centralized access to SEER's latest progress in enabling deep biological insights through proteomics. Check regularly for updates on how the company's integrated platform supports biomarker discovery and accelerates research across academic and commercial laboratories.
Seer, Inc. (Nasdaq: SEER) reported Q3 2022 revenue of $4.0 million, up from $2.2 million in Q3 2021, mainly due to increased sales of the Proteograph Product Suite. The gross profit was $1.9 million with a gross margin of 49%. Operating expenses rose to $27.0 million, leading to a net loss of $24.0 million, compared to a loss of $18.4 million in the previous year. Seer maintains a full-year revenue guidance of $14.0 million to $16.0 million.
Seer, Inc. (NASDAQ: SEER) will report its Q3 2022 financial results on November 8, 2022, at 1:30 p.m. PT. The conference call will be available via webcast on Seer's investor website, with a replay posted afterward. Seer specializes in developing innovative proteomics solutions through its Proteograph Product Suite, designed for quick and comprehensive analysis. This offering aims to enhance laboratory efficiency and accessibility.
Seer, a life sciences company based in Redwood City, California, announced its participation in the Morgan Stanley Global Healthcare Conference in New York City on September 13, 2022. Management will partake in a fireside chat at 8:35 a.m. Eastern Time. The session will be available via a live webcast on the company's investor website, with an archived replay to follow. Seer specializes in proteomics, offering the Proteograph Product Suite for deep proteomic analysis, designed for research use only.
Seer, Inc. announced the publication of a study demonstrating advancements in its Proteograph Product Suite for comprehensive proteomic analysis. The study, published in Advanced Materials, highlights the integration of proteomics methods, nanoengineering, and machine learning to capture thousands of proteins and discover novel biomarkers. CEO Omid Farokhzad emphasized the technology's capacity for deep interrogation of the proteome, enhancing research capabilities globally. The Proteograph suite combines engineered nanoparticles and software for rapid, scalable proteomics.
Seer, Inc. (Nasdaq: SEER) reported a revenue increase to $3.6 million for Q2 2022, up from $1.3 million in Q2 2021, driven by sales of the Proteograph Product Suite. The Proteograph™ Analysis Suite 2.0 was launched, enhancing their competitive edge in proteogenomics. However, the net loss for the quarter widened to $22.8 million compared to $16.6 million in the prior year. Operating expenses grew to $25.0 million, influenced by employee costs and facility expansions. The company maintains a full-year revenue guidance of $14.0 million to $16.0 million.
Seer Inc. (NASDAQ: SEER) announced the launch of its new Proteogenomics Workflow, integrating deep proteomics with genomics via the Proteograph Analysis Suite 2.0. This advancement allows for high-resolution, sample-specific analysis, enabling researchers to identify novel protein variants critical for health and disease understanding. The launch follows the formation of the Proteogenomics Consortium with Discovery Life Sciences and SCIEX to enhance biomarker discovery. The software is immediately available to customers, promoting broader access to advanced proteogenomics tools.
Seer Inc. (NASDAQ: SEER) has scheduled its second quarter 2022 financial results announcement for August 9, 2022, at 1:30 p.m. PT / 4:30 p.m. ET. The event will include a live webcast available on the investor section of its website, with an archived replay posted afterward. Seer is a life sciences company focused on innovative proteomics solutions, specifically through its Proteograph™ Product Suite, which enables efficient and scalable proteomic analysis designed for research purposes.
Seer, Inc. reported its first-quarter 2022 financial results, showing significant growth with $3.3 million in revenue, up from $62 thousand the previous year. This surge is attributed to the sales of the Proteograph Product Suite. The gross profit stood at $1.2 million with a 38% gross margin. However, operating expenses rose to $25 million, leading to a net loss of $23.6 million. Despite these losses, Seer anticipates full-year revenue between $14 million and $16 million, while expanding investments in commercial and R&D activities.
Seer, a life sciences company, will participate in the BofA Securities 2022 Healthcare Conference on May 10, 2022, at 4:40 p.m. PT. The event will feature a fireside chat with Seer's management, and interested parties can access a live webcast on the investor section of Seer's website. Seer's Proteograph Product Suite offers innovative solutions for deep proteomic analysis, designed for efficiency and ease of use. This platform is intended for research purposes only and is not for diagnostic procedures.
Seer Inc. (NASDAQ: SEER) will report its Q1 2022 financial results on May 4, 2022, followed by a conference call at 2:00 p.m. Pacific Time. The company is known for its innovative Proteograph Product Suite, designed for advanced proteomic analysis. This technology allows for deep, unbiased research capabilities, making it accessible to laboratories worldwide. The company emphasizes its focus on research use only, with no current diagnostic applications.
FAQ
What is the current stock price of Seer (SEER)?
What is the market cap of Seer (SEER)?
